

## Disclosures

### Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants ‡ Prediction of Cancer Therapeutics Related Cardiac Dysfunction and Major Adverse Cardiovascular Events in Cancer patients treated with potentially Cardiotoxic Agents	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Altathera	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
BridgeBio	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Myocardial Solutions	Research/Research Grants ‡ PROACT	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Race Oncology	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies Prevention

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)	Eidos Therapeutics	
Cardio-TTRansform	Ionis	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 10/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 10/3/2023

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private

endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.